Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
The existence of a vasoactive molecule released in response to hCG is believed to be the main feature in the development of ovarian hyperstimulation syndrome (OHSS) in women, and vascular endothelial growth factor (VEGF) is the main candidate as the human chorionic gonadotropin (hCG) mediator. This study was conducted to investigate the role of VEGF in increasing vascular permeability (VP) in vivo, a characteristic of OHSS. We analyzed the source and specific isoforms of VEGF involved and developed strategies to reverse increased VP in hyperstimulated rats targeting the VEGF system. Ovarian hyperstimulation was induced with pregnant mare's serum gonadotropin, or pregnant mare's serum gonadotropin plus hCG. Time-course experiments analyzed VP and the expression of whole VEGF mRNA in the mesentery and the ovaries. VP and ovarian mRNA VEGF expression increased to peak values after 48 h. No significant change in expression was observed in the mesentery. To further prove the ovarian origin of VEGF, we showed that VP was not altered when ovariectomized rats were treated with gonadotropins. The ovary expressed VEGF(120) and VEGF(164) isoforms. Immunohistochemistry showed VEGF in granulosa and zona pellucida of preovulatory and atretic follicles and in granulosa-lutein and endothelial cells of whole corpus luteum. A specific VEGF receptor-2 inhibitor (SU5416) was administered in three different protocols: on a daily basis, every 48 h, or two injections after hCG. Increased VP was reversed when SU5416 was administered every 48 h or two injections after hCG. These results show that the ovary is the main source of VEGF(120) and VEGF(164), which act through the VEGF receptor-2 to increase VP, and provide new insights into the prevention of OHSS.
Gómez
Raúl
R
Fundación IVI para el Estudio de la Reproducción, Valencia, Spain.
Simón
Carlos
C
Remohí
José
J
Pellicer
Antonio
A
D000818:Animals; D002199:Capillary Permeability / Q000502:physiology*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D003338:Corpus Luteum / Q000737:chemistry; D016228:Endothelial Growth Factors / Q000032:analysis / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006064:Gonadotropins, Equine / Q000008:administration & dosage; D006107:Granulosa Cells / Q000737:chemistry; D007150:Immunohistochemistry; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis / Q000235:genetics; D007700:Kinetics; D008222:Lymphokines / Q000032:analysis / Q000235:genetics; D008643:Mesentery / Q000098:blood supply / Q000378:metabolism; D016471:Ovarian Hyperstimulation Syndrome; D010052:Ovariectomy; D010053:Ovary / Q000098:blood supply / Q000378:metabolism; D010062:Ovulation Induction; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000502:physiology*; D042442:Vascular Endothelial Growth Factors; D015044:Zona Pellucida / Q000737:chemistry
D006063:Chorionic Gonadotropin; D016228:Endothelial Growth Factors; D006064:Gonadotropins, Equine; D007211:Indoles; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D011758:Pyrroles; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C116890:Semaxinib; D040301:Vascular Endothelial Growth Factor Receptor-2